Pacritinib

Pacritinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myelofibrosis、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis、Myelodysplastic Syndromes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Pacritinib 研究

• Pacritinib in CMML

  I 期 / II 期招募中美国NCT06159491

• Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

  II 期招募中西班牙NCT07394153

• Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

  I 期招募中美国NCT06675123

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  I 期 / II 期招募中美国NCT06303193

• Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

  早期 I 期招募中美国NCT06414681

• Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

  I 期招募中美国NCT06538181

• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

  II 期招募中美国NCT04282187

• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  II 期招募中美国比利时Bulgaria加拿大NCT05980806

• Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

  II 期招募中美国NCT06052618

• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

  II 期招募中美国NCT07447817

• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

  II 期招募中美国英国NCT07033598

• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

  II 期招募中美国NCT06986174

• Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

  II 期招募中美国NCT07226713

• A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  II 期招募中美国加拿大法国德国NCT06782373

• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

  I 期招募中美国NCT06218628

• Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

  II 期招募中美国NCT04858256

• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

  I 期 / II 期招募中美国NCT05531786

• Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

  II 期招募中美国NCT07148947

• Pacritinib Effectiveness in Real-world Settings

  不适用招募中美国NCT07774455

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。